Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017

Br J Dermatol. 2019 Jan;180(1):31-42. doi: 10.1111/bjd.17198.

G E van der Kraaij^{1

2

3}, D M W Balak⁴, C I Busard^{1

2}, O D van Cranenburgh^{1

5}, Y Chung³, R J B Driessen⁶, M de Groot⁷, E M G J de Jong^{6

8}, P M J H Kemperman^{1

9}, W J A de Kort¹⁰, S A Karsch³, A Lamberts^{3

11}, L L A Lecluse¹², P P M van Lümig⁶, S P Menting¹, E P Prens¹³, J M P A van den Reek⁶, M M B Seyger⁶, H B Thio¹³, W R Veldkamp^{3

8}, M Wakkee¹³, A Nast¹⁴, A Jacobs¹⁴, S Rosumeck¹⁴, P I Spuls Chair^{1

2}

¹ Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
² Public Health, Infection and Immunity, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
³ Dutch Society of Dermatology and Venereology, Utrecht, the Netherlands.
⁴ University Medical Centre Utrecht, Utrecht, the Netherlands.
⁵ Dutch Skin Foundation, Nieuwegein, the Netherlands.
⁶ Radboud University Medical Centre, Nijmegen, the Netherlands.
⁷ Antonius Hospital, Sneek/Emmeloord, the Netherlands.
⁸ Radboud University Nijmegen, the Netherlands.
⁹ Waterlandziekenhuis, Purmerend, the Netherlands.
¹⁰ Amphia Hospital, Breda, the Netherlands.
¹¹ University Medical Center Groningen, Groningen, the Netherlands.
¹² Bergman Clinics and U-clinic, Amsterdam, the Netherlands.
¹³ Erasmus Medical Centre, Rotterdam, the Netherlands.
¹⁴ Department of Dermatology, Venereology und Allergy, Division of Evidence-Based Medicine (dEBM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Abstract

Linked Comment: https://doi.org/10.1111/bjd.17390.